130880-38-5Relevant academic research and scientific papers
18F-labeled benzamides for studying the dopamine D2 receptor with positron emission tomography
Mach,Leudtke,Unsworth,Boundy,Nowak,Scripko,Elder,Jackson,Hoffman,Evora,Rao,Molinoff,Childers,Ehrenkaufer
, p. 3707 - 3720 (2007/10/02)
Two series of (N-benzylpiperidin-4-yl)- and (9-azabicyclo[3.3.1]nonan- 3β-yl)benzamides were prepared, and in vitro binding assays were used to measure the affinity of these compounds for dopamine D2, dopamine D3, serotonin 5-HT2, and α2-adrenergic receptors. The results of these studies indicated compounds 23, 26b, and 34 have the selectivity needed for in vivo studies of the D2 (and possibly D3) receptors. 18F-Labeled analogues of 23, 26b and 34 were prepared by N-alkylation of the corresponding desbenzyl precursors with [18F]-4-fluorobenzyl iodide. Preliminary in vivo studies demonstrated that [18F]-23 and [18F]-26b are suitable candidates for further evaluation in positron emission tomography imaging studies. The slow rate of washout of [18F]-34 from nondopaminergic regions and its comparatively high lipophilicity indicates that this compound may not be suitable for imaging studies because of a high level of nonspecific binding.
Potential antipsychotic agents. 6. Synthesis and antidopaminergic properties of substituted N-(1-benzyl-4-piperidinyl)salicylamides and related compounds. QSAR based design of more active members
De Paulis,Hall,Kumar,Ramsby,Ogren,Hogberg
, p. 507 - 517 (2007/10/02)
A number of substituted 2-methoxybenzamides, with and without 6-hydroxy groups, with 4-piperidinyl side-chains have been synthesized and evaluated for their antidopaminergic properties. The salicylamides were found to require a lipophilic N-substituent, like a benzyl group, for high affinity for the dopamine D-2 binding site in contrast to salicylamides with 2-pyrrolodinylmethyl side-chains. Furthermore, the influence of the aromatic substituents on the activity in the 2 series, ie 4-piperidinyl and 2-pyrrolidinylmethyl side-chains, was different. This was supported by a Hansch analysis, which could accomodate both phenolic and non-phenolic benzamides with 1-benzyl-4-piperidinyl side-chains. The activity is primarily dictated by electronic features rather than by steric and lipophilic properties. The QSAR equations were validated by the design and synthesis of a new 10-fold more active derivative. The 2 classes of benzamides with different side-chains are suggested to act on different binding sites or on different subtypes of the dopamine D-2 receptor.
